Saturday, 24 Oct 2026
Empowering Chinese Pharma’s Global Expansion
Contact US
Home
About US
Policy Hub
Categories
Drug
Company
Deals
Policy / Regulatory
Medical Device
R&D
Legal / IP
Digital
Privacy Policy
Contact US
My News
Cancer
Clinical trial approval / initiation
Product approvals
Clinical trial results
Finance
ADC / XDC
Finanical Reports
Biotech
Market approval filings
PD-1/L1
Read History
Search
Pages
Home
Blog Index
POLICY HUB
Contact Us
Personalized
Read History
Categories
Company
Drug
Policy / Regulatory
Medical Device
R&D
Digital
Legal / IP
Deals
Have an existing account?
Sign In
Follow US
Policy / Regulatory
China Unveils Ten Measures to Boost Family Doctor Contract Services
August 20, 2025
Company
Deals
Hunan FangSheng Pharmaceutical to Acquire JAK Inhibitor Patent Rights for RMB 80 Million
August 20, 2025
Company
Drug
Haihe Biopharma Seeks Japan Approval for Risovalisib in PIK3CA-Mutated Ovarian Cancer
August 20, 2025
Company
Deals
XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases
August 20, 2025
Company
Drug
Sino Biopharm’s LM-302 Shows Promising Results in Phase III Trials for Gastric Cancer
August 20, 2025
Company
Deals
GoodRx and Novo Nordisk Introduce $499 Monthly Pricing for Semaglutide Pens
August 20, 2025
Company
InnoCare Pharma’s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1
August 20, 2025
Company
Drug
China’s Zelgen Secures FDA IND Approval for Triple-Targeted Cancer Drug ZGGS34
August 20, 2025
Company
Hansoh’s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025
August 20, 2025
Company
Sichuan Kelun-Biotech Reports H1 Revenue Drop, Advances Key Drug Commercialization
August 20, 2025
Company
WuXi Biologics Reports 16.1% Revenue Growth in H1 2025, Launches WuXiHigh 2.0 Platform
August 20, 2025
Company
Drug
RemeGen’s RC148 Granted Breakthrough Therapy Designation for NSCLC Treatment
August 20, 2025
1
2
…
82
83
84
85
86
…
289
290
Welcome to Fineline Cube!
Username or Email Address
Password
Remember me
Lost your password?
